Search
Recently, Tianyikang Pharmaceutical (Shanghai) Co., Ltd. has proudly declared the successful closure of its seed funding round, amassing more than 100 million yuan. This significant financial boost was co-led by the esteemed Hony Capital and Med-Fine Capital, with additional support from a consortium of investors including Suzhou Innovation Investment, Chengshu Investment, Yingxian Investment, and Addor Capital. The infusion of capital will be strategically allocated towards advancing the research and development endeavors of in vivo multi-target cell therapy candidates. Furthermore, it will fuel the innovation and progression of next-generation universal multi-target CAR-T products, as well as the pioneering work on next-generation autologous rapid-process multi-target CAR-T cell therapy solutions.
-
C114 Communication Network -
Communication Home
